Loading...
Market
What regulatory action will Health Canada take on Neuralink's trial by November 2025?
2
Resolution / Starting Odds
No action taken • 25%
Trial paused • 25%
Additional conditions imposed • 25%
Trial revoked • 25%
Health Canada announcements or media reports
Story
Neuralink Receives Health Canada Approval for First Clinical Trial in Canada for Quadriplegia Patients at Toronto Western Hospital
Nov 20, 2024, 08:02 PM
Neuralink has received approval from Health Canada to initiate its first clinical trial in Canada, specifically targeting individuals with quadriplegia due to amyotrophic lateral sclerosis (ALS) or spinal cord injury (SCI). Recruitment for the trial is now open, and eligible participants can register through the company's Patient Registry. The trial will take place at Toronto Western Hospital, marking it as the first non-U.S. site for Neuralink's brain implant testing. The initiative aims to explore the transformative potential of brain-computer interfaces (BCIs) for individuals with severe mobility impairments.
View original story
Similar markets
Yes • 50%
No • 50%
New safety guidelines • 25%
Faster approval processes for BCI • 25%
Stricter regulations • 25%
No regulatory changes • 25%
Significant improvement in mobility • 25%
Moderate improvement in mobility • 25%
No improvement in mobility • 25%
Trial inconclusive • 25%
Successful with significant findings • 25%
Successful with limited findings • 25%
Unsuccessful • 25%
Indeterminate • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
